Order Article Reprints

Clark RE, Basabrain AA, Austin GM, Holcroft AK, Loaiza S, Apperley JF, Law C, Scott L, Parry AD, Bonnett L, et al. Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia. Cancers. 2021; 13(9):2155. https://doi.org/10.3390/cancers13092155

Clark, Richard E., Ammar A. Basabrain, Gemma M. Austin, Alison K. Holcroft, Sandra Loaiza, Jane F. Apperley, Christopher Law, Laura Scott, Alexandra D. Parry, Laura Bonnett, and et al. 2021. "Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia" Cancers 13, no. 9: 2155. https://doi.org/10.3390/cancers13092155

Clark, R. E., Basabrain, A. A., Austin, G. M., Holcroft, A. K., Loaiza, S., Apperley, J. F., Law, C., Scott, L., Parry, A. D., Bonnett, L., & Lucas, C. M. (2021). Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia. Cancers, 13(9), 2155. https://doi.org/10.3390/cancers13092155